Natera Acquires Invitae's Genetic Testing Assets
Ticker: NTRA · Form: 8-K · Filed: Jul 22, 2024 · CIK: 1604821
Sentiment: neutral
Topics: acquisition, healthcare, genetic-testing
Related Tickers: NVTA
TL;DR
Natera is buying Invitae's genetic testing business to boost its market share.
AI Summary
Natera, Inc. announced on July 19, 2024, that it has entered into a definitive agreement to acquire the assets of Invitae Corporation's genetic testing business. This strategic acquisition is expected to significantly expand Natera's capabilities in the genetic testing market.
Why It Matters
This acquisition could consolidate Natera's position in the genetic testing market and potentially lead to new service offerings or improved efficiency.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent integration risks, potential for unforeseen liabilities, and market reception uncertainties.
Key Players & Entities
- Natera, Inc. (company) — Registrant
- Invitae Corporation (company) — Target of acquisition
- July 19, 2024 (date) — Date of earliest event reported
FAQ
What specific assets of Invitae's genetic testing business is Natera acquiring?
The filing states Natera is acquiring the assets of Invitae Corporation's genetic testing business, but does not specify the exact assets in this 8-K filing.
What is the financial impact or purchase price of this acquisition?
The provided 8-K filing does not disclose the financial terms or purchase price of the acquisition.
When is the acquisition expected to be completed?
The filing does not specify an expected closing date for the acquisition.
Are there any regulatory approvals required for this acquisition?
The filing does not mention any specific regulatory approvals needed for the acquisition.
What is the strategic rationale behind Natera acquiring Invitae's genetic testing business?
The filing indicates the acquisition is expected to significantly expand Natera's capabilities in the genetic testing market, suggesting a strategic move to enhance its market position and offerings.
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-07-19 18:34:50
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NTRA Nasdaq Stock Market
- $287,500,000 — optional redemption right to redeem all $287,500,000 aggregate principal amount of its outst
Filing Documents
- tm2419819d1_8k.htm (8-K) — 25KB
- 0001104659-24-081215.txt ( ) — 194KB
- ntra-20240719.xsd (EX-101.SCH) — 3KB
- ntra-20240719_lab.xml (EX-101.LAB) — 33KB
- ntra-20240719_pre.xml (EX-101.PRE) — 22KB
- tm2419819d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On July 19, 2024, Natera, Inc. (the "Company") elected to exercise its optional redemption right to redeem all $287,500,000 aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2027 (the "Notes") and instructed Wilmington Trust, National Association, as trustee under the indenture governing the Notes, to issue a redemption notice to registered holders of the Notes. The date fixed for the redemption of the Notes is October 11, 2024 (the "Redemption Date"). The redemption price for the Notes is equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the Redemption Date.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Natera, Inc. By: /s/ Michael Brophy Michael Brophy Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) Dated: July 19, 2024